Literature DB >> 15728308

Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease.

D Ramirez-Montealegre1, S Chattopadhyay, T M Curran, C Wasserfall, L Pritchard, D Schatz, J Petitto, D Hopkins, J-X She, P G Rothberg, M Atkinson, D A Pearce.   

Abstract

The pathogenic mechanisms underlying Batten disease are unclear. Patients uniformly possess autoantibodies against glutamic acid decarboxylase (GAD) that are predominantly reactive with a region of GAD (amino acids 1 to 20) distinct from subjects with autoimmune type 1 diabetes or stiff-person syndrome. Batten patients did not possess autoantibodies against other type 1 diabetes-associated autoantigens and human leukocyte antigen genotypes revealed no specific associations with this disease.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15728308     DOI： 10.1212/01.WNL.0000151973.08426.7E

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  7 in total

1.  Loss of CNS IL-2 gene expression modifies brain T lymphocyte trafficking: response of normal versus autoreactive Treg-deficient T cells.

Authors:  Zhi Huang; Danielle Meola; John M Petitto
Journal:  Neurosci Lett       Date:  2011-06-06       Impact factor: 3.046

2.  Clinical and molecular characterization of non-syndromic retinal dystrophy due to c.175G>A mutation in ceroid lipofuscinosis neuronal 3 (CLN3).

Authors:  Fred K Chen; Xiao Zhang; Jonathan Eintracht; Dan Zhang; Sukanya Arunachalam; Jennifer A Thompson; Enid Chelva; Dominic Mallon; Shang-Chih Chen; Terri McLaren; Tina Lamey; John De Roach; Samuel McLenachan
Journal:  Doc Ophthalmol       Date:  2018-11-16       Impact factor: 2.379

3.  Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis).

Authors:  Erika F Augustine; Christopher A Beck; Heather R Adams; Sara Defendorf; Amy Vierhile; Derek Timm; Jill M Weimer; Jonathan W Mink; Frederick J Marshall
Journal:  JIMD Rep       Date:  2018-06-20

4.  A novel interaction of CLN3 with nonmuscle myosin-IIB and defects in cell motility of Cln3(-/-) cells.

Authors:  Amanda L Getty; Jared W Benedict; David A Pearce
Journal:  Exp Cell Res       Date:  2010-09-17       Impact factor: 3.905

5.  Immunosuppression alters disease severity in juvenile Batten disease mice.

Authors:  Sabrina S Seehafer; Denia Ramirez-Montealegre; Andrew Ms Wong; Chun-Hung Chan; Julian Castaneda; Michael Horak; Sarah M Ahmadi; Ming J Lim; Jonathan D Cooper; David A Pearce
Journal:  J Neuroimmunol       Date:  2011-01       Impact factor: 3.478

6.  Thymic alterations in GM2 gangliosidoses model mice.

Authors:  Seiichi Kanzaki; Akira Yamaguchi; Kayoko Yamaguchi; Yoshitsugu Kojima; Kyoko Suzuki; Noriko Koumitsu; Yoji Nagashima; Kiyotaka Nagahama; Michiko Ehara; Yoshio Hirayasu; Akihide Ryo; Ichiro Aoki; Shoji Yamanaka
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 7.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.